Chia Tai Tianqing Launches NPP for Urgent Cancer Treatment in Hong Kong
CompanyDeals

Chia Tai Tianqing Launches NPP for Urgent Cancer Treatment in Hong Kong

Innovent Biologics' IBI363 Granted Breakthrough Therapy Designation for Melanoma
CompanyDrug

Innovent Biologics’ IBI363 Granted Breakthrough Therapy Designation for Melanoma

NHC Data Reveals Digital Leap for Class 3 Hospitals Amid Drug Cost Crackdown
HospitalPolicy / Regulatory

NHC Data Reveals Digital Leap for Class 3 Hospitals Amid Drug Cost Crackdown

Hengrui's HRS-5965 Granted Breakthrough Therapy Designation for IgA Nephropathy
CompanyDrug

Hengrui’s HRS-5965 Granted Breakthrough Therapy Designation for IgA Nephropathy

Sanofi's Dupixent Approved in Japan for Chronic Obstructive Pulmonary Disease
CompanyDrug

Sanofi’s Dupixent Approved in Japan for Chronic Obstructive Pulmonary Disease

Pacific Shuanglin Bio-pharmacy Partners with XtalPi for Blood Product Innovation
CompanyDeals

Pacific Shuanglin Bio-pharmacy Partners with XtalPi for Blood Product Innovation

Novartis' Pluvicto Gains Expanded FDA Approval for Prostate Cancer Treatment
CompanyDrug

Novartis’ Pluvicto Gains Expanded FDA Approval for Prostate Cancer Treatment

EMA's CHMP Issues Negative Opinion on Lilly's Kisunla for Alzheimer's
CompanyDrug

EMA’s CHMP Issues Negative Opinion on Lilly’s Kisunla for Alzheimer’s

China's IAC Drafts Commercial Health Insurance Drug List A-Series to Bridge NRDL Coverage Gaps
Policy / Regulatory

China’s IAC Drafts Commercial Health Insurance Drug List A-Series to Bridge NRDL Coverage Gaps

China Scraps Outpatient Prepayment in Public Hospitals by 2025: Healthcare Reform Shifts Financial Burden
Policy / Regulatory

China Scraps Outpatient Prepayment in Public Hospitals by 2025: Healthcare Reform Shifts Financial Burden

uBriGene Appoints Dr. Joy Zhou to Lead Cell Therapy Development
Company

uBriGene Appoints Dr. Joy Zhou to Lead Cell Therapy Development

BMS's Opdivo/Yervoy Combo Approved by NMPA for First-Line HCC Treatment
CompanyDrug

BMS’s Opdivo/Yervoy Combo Approved by NMPA for First-Line HCC Treatment